These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 33781961

  • 1. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, attenuates apoptosis of vascular smooth muscle cells and reduces atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Li B, Luo YR, Zhang Q, Fu SH, Chen YD, Tian JW, Guo Y.
    Vascul Pharmacol; 2021 Oct; 140():106854. PubMed ID: 33781961
    [Abstract] [Full Text] [Related]

  • 2. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
    Lu HY, Huang CY, Shih CM, Chang WH, Tsai CS, Lin FY, Shih CC.
    PLoS One; 2015 Oct; 10(4):e0121077. PubMed ID: 25876091
    [Abstract] [Full Text] [Related]

  • 3. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.
    Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W, Wang L, He F, Xue Y.
    Cardiovasc Diabetol; 2014 Feb 04; 13():32. PubMed ID: 24490809
    [Abstract] [Full Text] [Related]

  • 4. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
    Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, Kanazawa A, Kawamori R, Fujitani Y, Watada H.
    Endocrinology; 2013 Mar 04; 154(3):1260-70. PubMed ID: 23337530
    [Abstract] [Full Text] [Related]

  • 5. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Matsubara J, Sugiyama S, Sugamura K, Nakamura T, Fujiwara Y, Akiyama E, Kurokawa H, Nozaki T, Ohba K, Konishi M, Maeda H, Izumiya Y, Kaikita K, Sumida H, Jinnouchi H, Matsui K, Kim-Mitsuyama S, Takeya M, Ogawa H.
    J Am Coll Cardiol; 2012 Jan 17; 59(3):265-76. PubMed ID: 22240132
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
    Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.
    Vascul Pharmacol; 2017 Sep 17; 96-98():19-25. PubMed ID: 28347868
    [Abstract] [Full Text] [Related]

  • 10. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
    Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y.
    J Cardiovasc Pharmacol; 2011 Aug 17; 58(2):157-66. PubMed ID: 21558879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice.
    Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.
    Vascul Pharmacol; 2016 Apr 17; 79():16-23. PubMed ID: 26277250
    [Abstract] [Full Text] [Related]

  • 13. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA, Lennox R, Flatt PR.
    Diabetes Obes Metab; 2015 Apr 17; 17(4):403-13. PubMed ID: 25580570
    [Abstract] [Full Text] [Related]

  • 14. Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice.
    Lin CP, Huang PH, Chen CY, Wu MY, Chen JS, Chen JW, Lin SJ.
    Sci Rep; 2021 Sep 08; 11(1):17851. PubMed ID: 34497344
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages.
    Brenner C, Franz WM, Kühlenthal S, Kuschnerus K, Remm F, Gross L, Theiss HD, Landmesser U, Kränkel N.
    Int J Cardiol; 2015 Nov 15; 199():163-9. PubMed ID: 26197403
    [Abstract] [Full Text] [Related]

  • 17. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice.
    Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y.
    Atherosclerosis; 2017 Jun 15; 261():44-51. PubMed ID: 28445811
    [Abstract] [Full Text] [Related]

  • 18. Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.
    Shirakawa J, Amo K, Ohminami H, Orime K, Togashi Y, Ito Y, Tajima K, Koganei M, Sasaki H, Takeda E, Terauchi Y.
    J Biol Chem; 2011 Jul 22; 286(29):25467-76. PubMed ID: 21613229
    [Abstract] [Full Text] [Related]

  • 19. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
    Samikannu B, Chen C, Lingwal N, Padmasekar M, Engel FB, Linn T.
    PLoS One; 2013 Jul 22; 8(12):e82639. PubMed ID: 24349326
    [Abstract] [Full Text] [Related]

  • 20. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A, Cabou C, Masseboeuf M, Cattan P, Armanet M, Karaca M, Castel J, Garret C, Payros G, Maida A, Sulpice T, Holst JJ, Drucker DJ, Magnan C, Burcelin R.
    Endocrinology; 2011 Aug 22; 152(8):3018-29. PubMed ID: 21673098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.